Dapagliflozin Versus Sacubitril-Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus.

Ariel HammermanJoseph AzuriEnis AboalhasanRonen Arbel

Published in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2021)

Dapagliflozin seems to offer greater value for money than the ARNI for patients with HFrEF and DM. Our results provide support for contemporary guidelines advocating the use of dapagliflozin in these patients.

Keyphrases

ejection fraction
end stage renal disease
chronic kidney disease
peritoneal dialysis
glycemic control
type diabetes
metabolic syndrome
clinical practice
skeletal muscle
adipose tissue
insulin resistance